Tag: hims & hers

  • Hims & Hers Rolls Out Weight-Loss and Prescription Platform in Australia

    Hims & Hers Rolls Out Weight-Loss and Prescription Platform in Australia

    Telehealth group Hims & Hers has launched branded GLP-1 weight-loss drugs and prescription treatments in Australia, chasing a global revenue target of US$6.5 billion by 2030.

    The rollout follows the completed acquisition of Sydney-based digital health firm Eucalyptus, which gave the US provider control of local men’s telehealth brand Pilot. Australian patients can now access treatments for sexual health, cholesterol and weight management directly through the combined digital channel.

    Integration of Pilot and Juniper

    Existing Pilot clinicians are shifting directly over to the Hims platform. A spokesperson for the company confirmed that the weight-loss catalogue includes access to branded GLP-1 medications, mirroring its US lineup of treatments such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.

    Former Eucalyptus chief executive Tim Doyle, who now serves as senior vice president at Hims & Hers, will oversee the Australian rollout. The company plans to bundle consultations and products that consumers previously bought as separate transactions, focusing on suburban and regional areas where physical access to specialists is limited.

    Digital health platforms across the Asia-Pacific region are consolidating fast to capture soaring consumer demand for metabolic care and discreet direct-to-consumer treatments. Local pharmacy operators face stiffer competition as international platforms buy up homegrown startups rather than building customer rosters from scratch.

    International Expansion and Margins

    Expanding across foreign markets has lifted monthly revenue per subscriber by 21 per cent year-on-year. That top-line gain comes with a cost: management told investors during its second-quarter earnings call that gross profit margins will stay below historical levels while international operations scale.

    The Australian launch builds on the 2025 purchase of London-based Zava, which distributes weight-loss drugs across the UK, Germany, France and Ireland. Next on the Australian schedule is the launch of its dedicated women’s health service through Eucalyptus brand Juniper before the end of the year.